Micro-Dose, Macro-Impact: Leveraging Psychedelics in Frontline Healthcare Workers During the COVID-19 Pandemic

NCT04769297 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Acute Stress Disorder

Interventions

DRUG: Sublingual Micro-Dose Ketamine

Sponsor

Limbic Medical

Collaborators

[object Object]